Polymer nanoparticles for cross-presentation of exogenous antigens and enhanced cytotoxic t-lymphocyte immune response

International Journal of Nanomedicine

Volumn 11, Issue , 2016, Pages 3753-3764

  Song, Chanyoung ^a   Noh, Young Woock ^a   Lim, Yong Taik ^a  

^a Sungkyunkwan University   (South Korea)

Author keywords

Antigen delivery; Cross presentation; Dendritic cells; Polymer NPs; Vaccine

Indexed keywords

ANTIGEN; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NANOPARTICLE; OVALBUMIN; POLYETHYLENEIMINE; POLYGLACTIN; POLYMER; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ANIMAL CELL; ARTICLE; BONE MARROW DERIVED DENDRITIC CELL; CANCER IMMUNOTHERAPY; CELL MATURATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; ENDOSOME; FEMALE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; INTERNALIZATION; LYSOSOME; MOUSE; NONHUMAN; PHAGOCYTOSIS; PINOCYTOSIS; SURFACE CHARGE; ANIMAL; C57BL MOUSE; CELL DIFFERENTIATION; CELL SURVIVAL; CHEMISTRY; CYTOLOGY; DENDRITIC CELL; ENDOCYTOSIS; IMMUNOLOGY; INTRACELLULAR SPACE; METABOLISM; ULTRASTRUCTURE;

ANIMALS; ANTIGENS; CELL DIFFERENTIATION; CELL SURVIVAL; CROSS-PRIMING; DENDRITIC CELLS; ENDOCYTOSIS; FEMALE; INTRACELLULAR SPACE; LACTIC ACID; MICE, INBRED C57BL; NANOPARTICLES; OVALBUMIN; POLYETHYLENEIMINE; POLYGLYCOLIC ACID; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84983268178     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S110796     Document Type: Article

References (29)

1. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161(2):505-522.
2. Irvine DJ, Hanson MC, Rakhra K, Tokatlian T. Synthetic nanoparticles for vaccines and immunotherapy. Chem Rev. 2015;115(19):11109-11146.
3. Shao K, Singha S, Clemente-Casares X, Tsai S, Yang Y, Santamaria P. Nanoparticle-based immunotherapy for cancer. ACS Nano. 2014;9(1):16-30.
4. Vasir JK, Labhasetwar V. Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv Drug Deliv Rev. 2007;59(8):718-728.
5. Yih TC, Al-Fandi M. Engineered nanoparticles as precise drug delivery systems. J Cell Biochem. 2006;97(6):1184-1190.
6. Friede M, Aguado MT. Need for new vaccine formulations and potential of particulate antigen and DNA delivery systems. Adv Drug Deliv Rev. 2005;57(3):325-331.
7. Heo MB, Lim YT. Programmed nanoparticles for combined immunomodulation, antigen presentation and tracking of immunotherapeutic cells. Biomaterials. 2014;35(1):590-600.
8. Noh YW, Hong JH, Shim SM, et al. Polymer nanomicelles for efficient mucus delivery and antigen-specific high mucosal immunity. Angew Chem Int Ed Engl. 2013;52(30):7684-7689.
9. Serda RE. Particle platforms for cancer immunotherapy. Int J Nanomedicine. 2013;8:1683-1696.
10. Caminschi I, Shortman K. Boosting antibody responses by targeting antigens to dendritic cells. Trends Immunol. 2012;33(2):71-77.
11. Gilboa E. DC-based cancer vaccines. J Clin Invest. 2007;117(5):1195-1203.
12. Lin ML, Zhan Y, Villadangos JA, Lew AM. The cell biology of cross-presentation and the role of dendritic cell subsets. Immunol Cell Biol. 2008;86(4):353-362.
13. Shen H, Ackerman AL, Cody V, et al. Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology. 2006;117(1):78-88.
14. Uto T, Wang X, Sato K, et al. Targeting of antigen to dendritic cells with poly(γ-glutamic acid) nanoparticles induces antigen-specific humoral and cellular immunity. J Immunol. 2007;178(5):2979-2986.
15. Tanaka Y, Taneichi M, Kasai M, Kakiuchi T, Uchida T. Liposome-coupled antigens are internalized by antigen-presenting cells via pinocytosis and cross-presented to CD8 T cells. PLoS One. 2010;5(12):e15225.
16. Xia X, Mai J, Xu R, et al. Porous silicon microparticle potentiates anti-tumor immunity by enhancing cross-presentation and inducing type I interferon response. Cell Rep. 2015;11(6):957-966.
17. Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM. Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. J Control Release. 2008;125(3):193-209.
18. Guedj AS, Kell AJ, Barnes M, et al. Preparation, characterization, and safety evaluation of poly(lactide-co-glycolide) nanoparticles for protein delivery into macrophages. Int J Nanomedicine. 2015;10:5965-5979.
19. Yu D, Zhang Y, Zhou X, Mao Z, Gao C. Influence of surface coating of PLGA particles on the internalization and functions of human endothelial cells. Biomacromolecules. 2012;13(10):3272-3282.
20. Fay F, Quinn DJ, Gilmore BF, McCarron PA, Scott CJ. Gene delivery using dimethyldidodecylammonium bromide-coated PLGA nanoparticles. Biomaterials. 2010;31(14):4214-4222.
21. Han R, Zhu J, Yang X, Xu H. Surface modification of poly(D,L-lactic-co-glycolic acid) nanoparticles with protamine enhanced cross-presentation of encapsulated ovalbumin by bone marrow-derived dendritic cells. J Biomed Mater Res A. 2011;96(1):142-149.
22. Intra J, Salem AK. Characterization of the transgene expression generated by branched and linear polyethylenimine-plasmid DNA nanoparticles in vitro and after intraperitoneal injection in vivo. J Control Release. 2008;130(2):129-138.
23. Kim SH, Jeong JH, Chun KW, Park TG. Target-specific cellular uptake of PLGA nanoparticles coated with poly(L-lysine)-poly(ethylene glycol)-folate conjugate. Langmuir. 2005;21(19):8852-8857.
24. Gómez JM, Csaba N, Fischer S, et al. Surface coating of PLGA microparticles with protamine enhances their immunological performance through facilitated phagocytosis. J Control Release. 2008;130(2):161-167.
25. Zhu L, Mahato RI. Lipid and polymeric carrier-mediated nucleic acid delivery. Expert Opin Drug Deliv. 2010;7(10):1209-1226.
26. Noh YW, Jang YS, Ahn KJ, Lim YT, Chung BH. Simultaneous in vivo tracking of dendritic cells and priming of an antigen-specific immune response. Biomaterials. 2011;32(26):6254-6263.
27. Goddette DW, Frieden C. Actin polymerization: the mechanism of action of cytochalasin D. J Biol Chem. 1986;261(34):15974-15980.
28. Porgador A, Yewdell JW, Deng Y, Bennink JR, Germain RN. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity. 1997;6(6):715-726.
29. Ackerman AL, Cresswell P. Cellular mechanisms governing cross-presentation of exogenous antigens. Nat Immunol. 2004;5(7):678-684.